- Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- Long-Term Safety of Donidalorsen for the Treatment of Hereditary Angioedema
• Donidalorsen is an investigational drug in late -stage development •Raffi Tachdjianhas received grants or research support from Astria Therapeutics, BioCryst, CSL Behring, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and Takeda; is a speaker for BioCryst, CSL Behring, Pharming, AstraZeneca, Sanofi-Regeneron Pharmaceuticals
- Isis Earns $5 Million in Milestone Payment from GSK for Advancement of . . .
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting . . .
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases
- Ionis Pharmaceuticals to hold 2018 financial results webcast
About Ionis Pharmaceuticals As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective
- ir. ionispharma. com
Address of Issuer Phone Name of Person for Whose Account the Securities are To Be Sold IONIS PHARMACEUTICALS INC 000-19125 2855 GAZELLE COURT CARLSBAD CALIFORNIA
- Ionis to present at upcoming investor conferences | Ionis . . .
Please check www ionispharma com for the latest information A live webcast of the presentations will be available on the Investors Media section of the Ionis website The replays will be available within 48 hours and will be archived for a limited time
- Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes . . .
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
|